Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely rilpivirine hydrochloride 25 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rilpivirine hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely rilpivirine hydrochloride 25 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Rilpivirine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely rilpivirine hydrochloride 25 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Rilpivirine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely rilpivirine hydrochloride 25 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Rilpivirine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely rilpivirine (as rilpivirine hydrochloride) 25 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rilpivirine hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely dolutegravir (as dolutegravir sodium) 50 milligram and rilpivirine (as rilpivirine hydrochloride) 25 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rilpivirine hydrochloride |
Inferred relationship |
Some |
1 |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir alafenamide (as tenofovir alafenamide fumarate) 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rilpivirine hydrochloride |
Inferred relationship |
Some |
2 |
Emtricitabine 200 mg and rilpivirine (as rilpivirine hydrochloride) 25 mg and tenofovir disoproxil (as tenofovir disoproxil fumarate) 245 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Rilpivirine hydrochloride |
Inferred relationship |
Some |
3 |